Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONCUR
  • Sponsors Bayer

    • Most Recent Events

    • 02 Jul 2022 Results of a network analysis of data pooled from 3 global (ReDOS, CORRECT, RECOURSE) and 3 Asian (TERRA, Yoshino 2012, and CONCUR) studies assessed the impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer
    • 08 Jun 2021 Results evaluating findings of the five-dimensions of HRQoL in the two trials (CORRECT and CONCUR) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 01 May 2020 Results from NCT01103323; NCT01271712; NCT01584830; NCT01774344 evaluating Population pharmacokinetics of regorafenib in solid tumors in clinical practice considering enterohepatic circulation and food intake, published in the British Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top